A new experimental medication may offer hope for reducing the risk of serious cardiovascular disease caused by high levels of lipoprotein (a), commonly known as Lp(a). Researchers recently reported that the drug, called lepodisiran, was able to lower Lp(a) concentrations in the blood by as much as 94% after only one injection. Scientists believe the treatment could eventually help prevent heart attacks, strokes, and sudden cardiac events in people with inherited cardiovascular risk factors.
Lp(a) is a fat-protein particle found in the bloodstream that is strongly linked to heart disease. Unlike traditional cholesterol, elevated Lp(a) levels are mainly determined by genetics and cannot usually be reduced through healthy eating, exercise, or commonly prescribed cholesterol medications. Many individuals are unaware they have high Lp(a) because routine testing is not always performed during standard medical checkups.
In the study, researchers observed that one dose of lepodisiran continued suppressing Lp(a) levels for nearly six months. Participants generally tolerated the medication well, and no major safety concerns were identified during the trial. According to scientists, this is an important development because people with significantly elevated Lp(a) face a much higher likelihood of developing cardiovascular disease, even if they do not have other common risk factors such as smoking, obesity, or high blood pressure.
Doctors involved in the research explained that high Lp(a) may help explain why some otherwise healthy individuals experience unexpected heart attacks at relatively young ages. While the early results are promising, experts caution that additional large-scale studies are necessary to confirm whether lowering Lp(a) directly reduces the number of heart attacks and strokes over time.
Researchers hope therapies targeting Lp(a) will eventually become part of routine cardiovascular prevention. Future studies may help doctors better identify hidden genetic risks and provide earlier treatment to patients who are vulnerable to serious heart disease.
